Bicycle Therapeutics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Bicycle Therapeutics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag2.8%
Nächster Dividendenzahlungsterminn/a
Ex-Dividendendatumn/a
Dividende pro Aktien/a
Gewinn pro Aktie-US$2.44
Erwartete Dividendenrendite in 3 Jahrenn/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert

May 24

Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

May 10
Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why

Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

May 04
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Apr 19
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 12

Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Jan 04
Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

Nov 07
Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

May 14
The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Mar 31
Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Mar 09
Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Nov 08
Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Bicycle Therapeutics: Exploring An Intriguing Developmental Platform

Oct 08

Bicycle Therapeutics initiated Outperform at Cowen citing drug platform

Aug 31

Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration

Jul 12

Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Jul 10
Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer

Jul 05

Bicycle Therapeutics: Trying To Catch This Falling Knife

Apr 17

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Apr 11
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Bicycle Therapeutics: A Buy Ahead Of AACR Presentation

Mar 25

Bicycle Therapeutics: An Oncology Play With Big Potential

Feb 28

Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Nov 07
Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles

Aug 25

The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

Aug 07
The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

May 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

Bicycle Therapeutics EPS misses by $0.05, beats on revenue

May 06

Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Mar 08
Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Feb 23
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von BCYC in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von BCYC gestiegen sind.


Dividendenrendite im Vergleich zum Markt

Bicycle Therapeutics Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von BCYC im Vergleich zum Markt aus?
SegmentDividendenrendite
Unternehmen (BCYC)n/a
Untere 25 % des Marktes (US)1.5%
Markt Top 25 % (US)4.8%
Branchendurchschnitt (Biotechs)2.8%
Analystenprognose in 3 Jahren (BCYC)n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von BCYC im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von BCYC im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.


Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von BCYC, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.


Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da BCYC keine Ausschüttungen gemeldet hat.


Entdecken Sie dividendenstarke Unternehmen